SPOTLIGHT -
SECO 2023: Neuro nuggets with Dr Lee
Andy Lee, MD, gives highlights from his SECO special session, "Neuro nuggets."
SECO 2023: Glaucoma treatments in the optometrist's wheelhouse
Nate Lighthizer, OD, gives highlights from his SECO 2023 presentation, "The glaucoma compass."
SECO 2023: Pipeline update from Tarsus
Tarsus has received a PDUFA date for their TP-03 drug, which they are hoping to bring to market later this year.
Pharmedica USA Purely Soothing 15% MSM eye drops recalled due to non-sterility
Contaminated Purely Soothing 15% MSM drops carry risk of eye infections that may result in vision loss. All consumers should stop use immediately.
SECO 2023: Learning about the lids
Mile Brujic, OD, shares highlights from his SECO 2023 presentation, "Learning about the Lid: Optimizing recognition, diagnosis, and treatment of Demodex blepharitis and blepharoptosis."
Recall of brimonidine tartrate ophthalmic solution voluntarily issued by Apotex Corp.
This recall is being initiated out of an abundance of caution due to cracks that have developed in some of the units caps of brimonidine tartrate ophthalmic solution bottles
SECO 2023: Incorporating confocal scanning laser imaging in practice
Mile Brujic, OD, shares highlights from his SECO 2023 poster presentation on confocal scanning laser imaging and patient care.
SECO 2023: Hot news or not news?
Chris Wroten, OD, shares key takeaways from his "Hot news or not news?" presentation at SECO 2023.
SECO 2023: Lasers in optometry: The next frontier
Nate Lighthizer, OD, shares what to expect from his SECO workshop, "Lasers in Optometry: The Next Frontier."
SECO 2023: Orasis Pharmaceuticals presents pipeline update at OIS
Paul Smith shares an update on Orasis Pharmaceutical's CSF-1 drug and what to expect this year.
SECO 2023: Keeping an eye on geographic atrophy
Mohammed Rafieetary, OD, shares key takeaways from his SECO 2023 presentation, "Advancing the understanding of geographic atrophy."
SECO 2023: Caring for myopic patients through lifestyle interventions
Ashley Wallace-Tucker, OD, FAAO, FSLS, Dipl ABO, shares key takeaways from her SECO 2023 panel discussion, "Myopia management."
SECO 2023: Laser workshop for optometrists
Chris Wroten, OD, shares highlights from the hands-on laser workshop he co-led during SECO 2023.
This week in optometry: February 25-March 2
A look back on what's happened in optometry during the week of February 25-March 2.
SECO 2023: Drugs of the future
Milton M. Hom, OD, FAAO, FACAAI (Sc), shares key takeaways from his SECO 2023 presentation, "Drugs of the future."
SECO 2023: Valuing your contact lens patients, while valuing yourself
Shalu Pal, BSc, OD, FAAO, shares key takeaways from the contact lens zpanel discussion she participated in.
SECO 2023: Contact lenses for presbyopic patients
Milton M. Hom, OD, FAAO, FACAAI (Sc), shares key highlights from his portion of the "Presbyopia management panel," during SECO 2023 in Atlanta.
Practical management EP 6: Importance of increasing revenue
Continuing the conversation on practice management, Maria Sampalis, OD, shares why increasing revenue is important for a sustainable optometric practice.
CooperVision’s MyDays Energys contact lenses hit US market
First 1-Day Lens that combines DigitalBoost and Aquaform technologies designed to deliver comfort for ‘always on’ digital lifestyles
Poll results: How comfortable are you with including biosimilars in your treatment plans?
See the results from our recent poll!
This week in optometry: February 18-February 23
A look back on what's happened in optometry during the week of February 18-February 23.
Practical management EP 5: Utilizing digital platforms
In this episode of a practice management series, Maria Sampalis, OD, touches on digital platforms and the importance of utilizing them.
Controversies in Modern Eye Care 2023: Back to in-person and better than before
Arjan Hura, MD, gives a sneak peek of the 17th annual Controversies in Modern Eye Care meeting being held this April in Los Angeles.
Pegcetacoplan approved by FDA for the treatment of geographic atrophy
Following the submission of the 24-month phase 3 data in November 2022, Apellis received FDA approval for intravitreal pegcetacoplan (SYFOVRE) to treat geographic atrophy secondary to AMD.
Vision Expo East announces 2023 keynote speaker
Jason Romero, a legally blind ultra-runner, will be giving the keynote address at the 2023 Vision Expo East meeting March 16-19 in New York City.
This week in optometry: February 11-February 16
A look back on what's happened in optometry during the week of February 11-February 16.
IKA Keratoconus Symposium 2023: Sneak peek with Dr Szczotka-Flynn
Loretta Szczotka-Flynn, OD, PhD, sits down to discuss the International Keratoconus Academy's first annual keratoconus symposium, which will be held April 22-23, 2023, in Scottsdale, Arizona.
Practical management EP 4: Online promotions
In this episode of a practice management series with Maria Sampalis, OD, learn about different online promotions and how to put them into practice.
Poll: How comfortable are you with including biosimilars in your treatment plans?
Vote in our most recent poll!
Poll results: Have you referred a patient with AMD for a low vision evaluation?